European Market Report for Transcervical Female Sterilization
|出版商||iData Research Inc.||商品編碼||371088|
|出版日期||內容資訊||英文 62 Pages
|歐洲的女性用·子宮頸避孕設備市場分析 European Market Report for Transcervical Female Sterilization|
|出版日期: 2016年09月01日||內容資訊: 英文 62 Pages||
The transcervical implant market in Europe currently consists of Bayer AG as the sole competitor offering the Essure® product. Essure® was first developed by the company Conceptus in 2001 and was certified for sale throughout Europe, with the first sale occurring in October 2002. In the United States, Essure® was subsequently approved by the FDA on November 4th, 2002. In April 2013, Bayer AG acquired Conceptus to offer Essure® as part of their contraceptive portfolio. In the United Kingdom, the National Institute for Health and Care Excellence approved Essure® in 2009, the last European country to do so. Since Essure® entered the market in 2002, other notable competitors have been the Ovabloc System and the Adiana procedure. Both of these procedures have since been discontinued.
Female sterilization is a permanent form of birth control, requiring invasive surgery to reverse. Female sterilization prevents ova from coming down the fallopian tubes and blocks fertilization by sperm. There are different procedures to perform female sterilization, including tubal ligation, mechanical blockage with a clip or band, bipolar electrocoagulation or transcervical implants. In this report, only the transcervical implant market is covered.